Back to TWO SIGMA INVESTMENTS, LP TWO SIGMA INVESTMENTS, LP

RARERARE
26 quarters

Position history for TWO SIGMA INVESTMENTS, LPTWO SIGMA INVESTMENTS, LP's holdings in ULTRAGENYX PHARMACEUTICAL IN

TWO SIGMA INVESTMENTS, LP holds 2.2M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), worth $46.2M as of 2026-Q1. The position was increased (+420.2% shares). RARE represents 0.0% of TWO SIGMA INVESTMENTS, LP's portfolio.

Current Value

$46.2M

Current Shares

2.2M

Total Value Change

+$45.9M

Total Shares Change

+2.2M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
2.2M
+420.2%
$46.2M0.0%$22.07
47
2025-Q4
Increased
424,049
+30.0%
$9.8M0.0%$22.78
35
2025-Q3
Decreased
326,180
-43.5%
$9.8M0.0%$30.36
0
2025-Q2
Decreased
576,901
-8.9%
$21M0.0%$36.52
0
2025-Q1
Increased
633,152
+3.0%
$22.9M0.0%$37.82
29
2024-Q4
Decreased
614,948
-18.6%
$25.9M0.1%$42.27
0
2024-Q3
Increased
755,683
+33.0%
$42M0.1%$54.43
37
2024-Q2
Increased
568,309
+36.8%
$23.4M0.1%$41.10
37
2024-Q1
Increased
415,314
+228.0%
$19.4M0.0%$46.69
46
2023-Q4
Increased
126,610
+223.0%
$6.1M0.0%$47.82
44
2023-Q3
Decreased
39,200
-90.3%
$1.4M0.0%$35.65
0
2023-Q2
Decreased
403,774
-17.3%
$18.6M0.0%$46.65
0
2023-Q1
Increased
488,356
+10.5%
$19.6M0.1%$38.64
31
2022-Q4
Increased
441,936
+73.0%
$20.5M0.1%$46.33
43
2022-Q3
Increased
255,389
+352.0%
$10.6M0.0%$40.55
45
2022-Q2
Increased
56,500
+45.2%
$3.4M0.0%$60.24
36
2022-Q1
New
38,900
-
$2.8M0.0%$71.36
36
2021-Q4
Exited
0
-100.0%
$00.0%$84.25
0
2021-Q3
Decreased
25,900
-91.1%
$2.3M0.0%$86.12
0
2021-Q2
Increased
290,264
+101.1%
$27.7M0.1%$96.29
46
2021-Q1
Increased
144,320
+139.3%
$16.4M0.0%$112.06
45
2020-Q4
Increased
60,312
+955.0%
$8.3M0.0%$144.37
44
2020-Q3
Decreased
5,717
-85.5%
$470,0000.0%$85.10
0
2020-Q2
New
39,554
-
$3.1M0.0%$73.66
37
2019-Q4
Exited
0
-100.0%
$00.0%$42.69
0
2019-Q3
New
7,759
-
$332,0000.0%$42.50
33

Other major holders of RARE: Capital Research Global Investors, Capital International Investors, FEDERATED HERMES, INC.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used